NCT06241326Recruiting
Immunotherapy for Hepatocellular Carcinoma
A Real-world Study of Immunotherapy-based Combination Therapies in Chinese Patients With Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 10 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 11000 (estimated)
- First submitted
- 28 Jan 2024
- Start date
- 1 Mar 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06241326
What you commit to
- Study type: Observational
- Planned participants: 11000
- From 1 Mar 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other conditions regimented at investigators' discretion.
Other
- Pregnant or lactating women.
Who the study is looking for
- Aged after 18 years (18 is included).
- Hepatocellular carcinoma diagnosed by pathology or imaging.
- Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens.
- For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations.
- Patients voluntarily enroll in this study.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jiangsu Province Hospital Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.